Organon & Co. (NYSE:OGN) Sets New 1-Year Low - Here's Why

Organon & Co. (NYSE:OGN - Get Free Report)'s stock price reached a new 52-week low on Wednesday . The company traded as low as $10.89 and last traded at $10.93, with a volume of 294850 shares trading hands. The stock had previously closed at $11.05.

Wall Street Analyst Weigh In

OGN has been the subject of several recent analyst reports. Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Morgan Stanley lowered their price target on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Finally, TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Organon & Co. has a consensus rating of "Hold" and an average price target of $20.60.

Organon & Co. Price Performance

The company's 50-day simple moving average is $14.25 and its 200 day simple moving average is $15.39. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of 3.34, a P/E/G ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Equities research analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 10.08%. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Horizon Bancorp Inc. IN increased its stake in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after purchasing an additional 1,585 shares during the period. Millstone Evans Group LLC acquired a new stake in Organon & Co. in the 4th quarter valued at approximately $29,000. Larson Financial Group LLC increased its position in Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after buying an additional 1,734 shares during the period. Riverview Trust Co increased its position in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after buying an additional 1,292 shares during the period. Finally, Versant Capital Management Inc lifted its holdings in shares of Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock worth $41,000 after buying an additional 1,324 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.